MTOR and chronic myelogenous leukemia, BCR-ABL1 positive: Additionally, 16 oar-miR-23b target genes were individually enriched in pathways including focal adhesion, transcriptional misregulation in cancer, the ErbB signaling pathway, the mTOR signaling pathway, renal cell carcinoma, chronic myeloid leukemia, non-small-cell lung cancer, EGFR tyrosine kinase inhibitor resistance, microRNAs in cancer, etc. (Figure S3).